India
Bugworks Research Inc., founded in 2014, is a dynamic player in the biotechnology, health care, life sciences, and pharmaceutical industries. Headquartered in India, the company is dedicated to addressing significant unmet needs through its innovative approaches in tackling Antimicrobial Resistance (AMR) and immuno-oncology.
With the slogan “Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology,” Bugworks is committed to making its highly differentiated medical assets both affordable and accessible globally. This mission positions them as a critical entity in the global health landscape, a factor that underscores their potential high-impact value.
The company recently secured a substantial $6.78M Venture Round investment on 08 March 2024, reflecting investor confidence in their distinctive capabilities and market-focused strategies. Though specific investor details remain undisclosed, this funding consolidates Bugworks’ traction and prospects for substantial growth in combating pressing health challenges.
